NCT05404230Recruiting
Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities
Prevention of Oxaliplatin-induced Peripheral Neuropathy - a Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 30 May 2022
- Start date
- 15 Jul 2022
- Primary completion date
- Dec 2027
- Lead sponsor
- Vejle Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT05404230
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 15 Jul 2022 to the primary completion date, Dec 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment with neurotoxic chemotherapy.
- Alcohol or drug abuse.
Other illness
- Neurological (including neuropathy) or psychiatric disorders, diabetes or other significant medical conditions.
- Vascular disease (Fontaine grade II or more).
- Known allergy to fish, fish oil or corn oil
Other
- Inability to speak, read, and understand Danish.
- Sensory disturbances in the feet
- Spinal stenosis.
- Fertile patients not willing to use effective methods of contraception during treatment or abstinence.
- Daily intake of oil supplements and not willing to stop during the trial period.
- Lack of consent to skin biopsy
Who the study is looking for
- Histopathologically verified adenocarcinoma of the colon or rectum and planned standard adjuvant treatment with capecitabine in combination with oxaliplatin.
- ECOG performance status 0-2 (measurement of a patient's function in terms of self-care, daily activity and physical ability.
- Written and orally informed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Oncology, AAUH Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
| Department of Oncology, AUH Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
| Department of Oncology Coordinator of this site? Confirm its status | Sønderborg | Denmark | Recruiting |
| Department of Oncology, Vejle Hospital Coordinator of this site? Confirm its status | Vejle | Denmark | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.